Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Recurrent gBRCAm Ovarian Cancer
NCT02326844Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in ovarian cancer, sponsored by National Cancer Institute. Started Mar 2015; status: terminated.
02
Drugs
talazoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02326844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326844.